Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic

Disease modifying therapies and Covid‐19 severity in Multiple Sclerosis

(2021) Maria Pia Sormani et al.   ANNALS OF NEUROLOGY

Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic

(2020) Wallace Brownlee et al.   NEUROLOGY

Personalized extended interval dosing of natalizumab in MS

(2020) Zoé L.E. van Kempen et al.   NEUROLOGY

The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.

(2020) David Baker et al.   Multiple Sclerosis and Related Disorders

Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness

(2020) Barbara Barun et al.   Multiple Sclerosis and Related Disorders

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein

(2017) Lenka Novakova et al.   NEUROLOGY

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2017) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients

(2015)   Nature Reviews Neurology

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

(2011) Ludwig Kappos et al.   LANCET